Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET

Head-to-head comparison

Anna Caroli, Annapaola Prestia, Kewei Chen, Napatkamon Ayutyanont, Susan M. Landau, Cindee M. Madison, Cathleen Haense, Karl Herholz, Flavio Nobili, Eric M. Reiman, William J. Jagust, Giovanni B. Frisoni

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

In the recently revised diagnostic criteria for Alzheimer disease (AD), the National Institute on Aging and Alzheimer Association suggested that confidence in diagnosing dementia due to AD and mild cognitive impairment (MCI) due to AD could be improved by the use of certain biomarkers, such as 18F-FDG PET evidence of hypometabolism in AD-affected brain regions. Three groups have developed automated data analysis techniques to characterize the AD-related pattern of hypometabolism in a single measurement. In this study, we sought to directly compare the ability of these three 18F-FDG PET data analysis techniques - the PMOD Alzheimer discrimination analysis tool, the hypometabolic convergence index, and a set of meta-analytically derived regions of interest reflecting AD hypometabolism pattern (metaROI) - to distinguish moderate or mild AD dementia patients and MCI patients who subsequently converted to AD dementia from cognitively normal older adults. Methods: One hundred sixty-six 18F-FDG PET patients from the AD Neuroimaging Initiative, 308 from the Network for Efficiency and Standardization of Dementia Diagnosis, and 176 from the European Alzheimer Disease Consortium PET study were categorized, with masking of group classification, as AD, MCI, or healthy control. For each AD-related 18F-FDG PET index, receiver-operating-characteristic curves were used to characterize and compare subject group classifications. Results: The 3 techniques were roughly comparable in their ability to distinguish each of the clinical groups from cognitively normal older adults with high sensitivity and specificity. Accuracy of classification (in terms of area under the curve) in each clinical group varied more as a function of dataset than by technique. All techniques were differentially sensitive to disease severity, with the classification accuracy for MCI due to AD to moderate AD varying from 0.800 to 0.949 (PMOD Alzheimer tool), from 0.774 to 0.967 (metaROI), and from 0.801 to 0.983 (hypometabolic convergence index). Conclusion: The 3 tested techniques have the potential to help detect AD in research and clinical settings. Additional efforts are needed to clarify their ability to address particular scientific and clinical questions. Their incremental diagnostic value over other imaging and biologic markers makes them easier to implement by other groups for these purposes. COPYRIGHT

Original languageEnglish
Pages (from-to)592-600
Number of pages9
JournalJournal of Nuclear Medicine
Volume53
Issue number4
DOIs
Publication statusPublished - Apr 1 2012

Fingerprint

Fluorodeoxyglucose F18
Alzheimer Disease
Aptitude
Dementia
National Institute on Aging (U.S.)
Biomarkers
Neuroimaging
ROC Curve

Keywords

  • Alzheimer disease
  • Diagnostic performance
  • FDG PET summary metrics
  • Hypometabolism

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET : Head-to-head comparison. / Caroli, Anna; Prestia, Annapaola; Chen, Kewei; Ayutyanont, Napatkamon; Landau, Susan M.; Madison, Cindee M.; Haense, Cathleen; Herholz, Karl; Nobili, Flavio; Reiman, Eric M.; Jagust, William J.; Frisoni, Giovanni B.

In: Journal of Nuclear Medicine, Vol. 53, No. 4, 01.04.2012, p. 592-600.

Research output: Contribution to journalArticle

Caroli, A, Prestia, A, Chen, K, Ayutyanont, N, Landau, SM, Madison, CM, Haense, C, Herholz, K, Nobili, F, Reiman, EM, Jagust, WJ & Frisoni, GB 2012, 'Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET: Head-to-head comparison', Journal of Nuclear Medicine, vol. 53, no. 4, pp. 592-600. https://doi.org/10.2967/jnumed.111.094946
Caroli, Anna ; Prestia, Annapaola ; Chen, Kewei ; Ayutyanont, Napatkamon ; Landau, Susan M. ; Madison, Cindee M. ; Haense, Cathleen ; Herholz, Karl ; Nobili, Flavio ; Reiman, Eric M. ; Jagust, William J. ; Frisoni, Giovanni B. / Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET : Head-to-head comparison. In: Journal of Nuclear Medicine. 2012 ; Vol. 53, No. 4. pp. 592-600.
@article{9440577208b2431f9410bdc3dd2fc8c7,
title = "Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET: Head-to-head comparison",
abstract = "In the recently revised diagnostic criteria for Alzheimer disease (AD), the National Institute on Aging and Alzheimer Association suggested that confidence in diagnosing dementia due to AD and mild cognitive impairment (MCI) due to AD could be improved by the use of certain biomarkers, such as 18F-FDG PET evidence of hypometabolism in AD-affected brain regions. Three groups have developed automated data analysis techniques to characterize the AD-related pattern of hypometabolism in a single measurement. In this study, we sought to directly compare the ability of these three 18F-FDG PET data analysis techniques - the PMOD Alzheimer discrimination analysis tool, the hypometabolic convergence index, and a set of meta-analytically derived regions of interest reflecting AD hypometabolism pattern (metaROI) - to distinguish moderate or mild AD dementia patients and MCI patients who subsequently converted to AD dementia from cognitively normal older adults. Methods: One hundred sixty-six 18F-FDG PET patients from the AD Neuroimaging Initiative, 308 from the Network for Efficiency and Standardization of Dementia Diagnosis, and 176 from the European Alzheimer Disease Consortium PET study were categorized, with masking of group classification, as AD, MCI, or healthy control. For each AD-related 18F-FDG PET index, receiver-operating-characteristic curves were used to characterize and compare subject group classifications. Results: The 3 techniques were roughly comparable in their ability to distinguish each of the clinical groups from cognitively normal older adults with high sensitivity and specificity. Accuracy of classification (in terms of area under the curve) in each clinical group varied more as a function of dataset than by technique. All techniques were differentially sensitive to disease severity, with the classification accuracy for MCI due to AD to moderate AD varying from 0.800 to 0.949 (PMOD Alzheimer tool), from 0.774 to 0.967 (metaROI), and from 0.801 to 0.983 (hypometabolic convergence index). Conclusion: The 3 tested techniques have the potential to help detect AD in research and clinical settings. Additional efforts are needed to clarify their ability to address particular scientific and clinical questions. Their incremental diagnostic value over other imaging and biologic markers makes them easier to implement by other groups for these purposes. COPYRIGHT",
keywords = "Alzheimer disease, Diagnostic performance, FDG PET summary metrics, Hypometabolism",
author = "Anna Caroli and Annapaola Prestia and Kewei Chen and Napatkamon Ayutyanont and Landau, {Susan M.} and Madison, {Cindee M.} and Cathleen Haense and Karl Herholz and Flavio Nobili and Reiman, {Eric M.} and Jagust, {William J.} and Frisoni, {Giovanni B.}",
year = "2012",
month = "4",
day = "1",
doi = "10.2967/jnumed.111.094946",
language = "English",
volume = "53",
pages = "592--600",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "4",

}

TY - JOUR

T1 - Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET

T2 - Head-to-head comparison

AU - Caroli, Anna

AU - Prestia, Annapaola

AU - Chen, Kewei

AU - Ayutyanont, Napatkamon

AU - Landau, Susan M.

AU - Madison, Cindee M.

AU - Haense, Cathleen

AU - Herholz, Karl

AU - Nobili, Flavio

AU - Reiman, Eric M.

AU - Jagust, William J.

AU - Frisoni, Giovanni B.

PY - 2012/4/1

Y1 - 2012/4/1

N2 - In the recently revised diagnostic criteria for Alzheimer disease (AD), the National Institute on Aging and Alzheimer Association suggested that confidence in diagnosing dementia due to AD and mild cognitive impairment (MCI) due to AD could be improved by the use of certain biomarkers, such as 18F-FDG PET evidence of hypometabolism in AD-affected brain regions. Three groups have developed automated data analysis techniques to characterize the AD-related pattern of hypometabolism in a single measurement. In this study, we sought to directly compare the ability of these three 18F-FDG PET data analysis techniques - the PMOD Alzheimer discrimination analysis tool, the hypometabolic convergence index, and a set of meta-analytically derived regions of interest reflecting AD hypometabolism pattern (metaROI) - to distinguish moderate or mild AD dementia patients and MCI patients who subsequently converted to AD dementia from cognitively normal older adults. Methods: One hundred sixty-six 18F-FDG PET patients from the AD Neuroimaging Initiative, 308 from the Network for Efficiency and Standardization of Dementia Diagnosis, and 176 from the European Alzheimer Disease Consortium PET study were categorized, with masking of group classification, as AD, MCI, or healthy control. For each AD-related 18F-FDG PET index, receiver-operating-characteristic curves were used to characterize and compare subject group classifications. Results: The 3 techniques were roughly comparable in their ability to distinguish each of the clinical groups from cognitively normal older adults with high sensitivity and specificity. Accuracy of classification (in terms of area under the curve) in each clinical group varied more as a function of dataset than by technique. All techniques were differentially sensitive to disease severity, with the classification accuracy for MCI due to AD to moderate AD varying from 0.800 to 0.949 (PMOD Alzheimer tool), from 0.774 to 0.967 (metaROI), and from 0.801 to 0.983 (hypometabolic convergence index). Conclusion: The 3 tested techniques have the potential to help detect AD in research and clinical settings. Additional efforts are needed to clarify their ability to address particular scientific and clinical questions. Their incremental diagnostic value over other imaging and biologic markers makes them easier to implement by other groups for these purposes. COPYRIGHT

AB - In the recently revised diagnostic criteria for Alzheimer disease (AD), the National Institute on Aging and Alzheimer Association suggested that confidence in diagnosing dementia due to AD and mild cognitive impairment (MCI) due to AD could be improved by the use of certain biomarkers, such as 18F-FDG PET evidence of hypometabolism in AD-affected brain regions. Three groups have developed automated data analysis techniques to characterize the AD-related pattern of hypometabolism in a single measurement. In this study, we sought to directly compare the ability of these three 18F-FDG PET data analysis techniques - the PMOD Alzheimer discrimination analysis tool, the hypometabolic convergence index, and a set of meta-analytically derived regions of interest reflecting AD hypometabolism pattern (metaROI) - to distinguish moderate or mild AD dementia patients and MCI patients who subsequently converted to AD dementia from cognitively normal older adults. Methods: One hundred sixty-six 18F-FDG PET patients from the AD Neuroimaging Initiative, 308 from the Network for Efficiency and Standardization of Dementia Diagnosis, and 176 from the European Alzheimer Disease Consortium PET study were categorized, with masking of group classification, as AD, MCI, or healthy control. For each AD-related 18F-FDG PET index, receiver-operating-characteristic curves were used to characterize and compare subject group classifications. Results: The 3 techniques were roughly comparable in their ability to distinguish each of the clinical groups from cognitively normal older adults with high sensitivity and specificity. Accuracy of classification (in terms of area under the curve) in each clinical group varied more as a function of dataset than by technique. All techniques were differentially sensitive to disease severity, with the classification accuracy for MCI due to AD to moderate AD varying from 0.800 to 0.949 (PMOD Alzheimer tool), from 0.774 to 0.967 (metaROI), and from 0.801 to 0.983 (hypometabolic convergence index). Conclusion: The 3 tested techniques have the potential to help detect AD in research and clinical settings. Additional efforts are needed to clarify their ability to address particular scientific and clinical questions. Their incremental diagnostic value over other imaging and biologic markers makes them easier to implement by other groups for these purposes. COPYRIGHT

KW - Alzheimer disease

KW - Diagnostic performance

KW - FDG PET summary metrics

KW - Hypometabolism

UR - http://www.scopus.com/inward/record.url?scp=84859406520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859406520&partnerID=8YFLogxK

U2 - 10.2967/jnumed.111.094946

DO - 10.2967/jnumed.111.094946

M3 - Article

VL - 53

SP - 592

EP - 600

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 4

ER -